Clinical Trail of Tang-min-Ling Pills in Type 2 Diabetes Mellitus

Launched by GUANG'ANMEN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES · Mar 15, 2010

Keywords

ClinConnect Summary

Type 2 diabetes mellitus combined liver-stomach heat retension syndrome were recruited, which were divided into 3 groups .The patients were randomly taken with high-dosage (12g Tang-min-ling pills every time), low-dosage (6g Tang-min-ling pills every time), placebo by 3 times every day for 12 weeks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • initial treatment type 2 diabetic patient
• • liver-stomach heat retention syndrome
• • BMI ≥24kg/m2
• • aged 30-65 years
• • after screening stage(lifestyle intervention),Hba1C≥7.0%,FPG7.0-13.3mmol/L or PG2h\>11.1mmol/L;
• • voluntary signs the informed consent
• Exclusion Criteria:
• • have used anti-diabetes drug before more than 1 month
• • used drug to control the blood sugar with 3 weeks
• • diabetic ketosis,keto-acidosis,serious infection or trauma,major surgery within 1 month
• • liver or kidney insufficiency,lung insufficiency,heart failure,acute myocardial infarction or other serious primary disease
• • SBP/DBP \>160mmHg/100 mmHg
• • serious chronic diabetic complication
• • chronic stomach-intestine disease,bad condition of the whole body
• • pregnancy,preparing to pregnant,or breast-feed stage women
• • allergic to TCM component
• • mental disease
• • allergic habitus
• • attending to other clinical test
• • attended this test before
• • bibulosity and/or mental active drug,drug abuse or depend
• • usually change the working environment,unstable live environment,etc.which will complied the inclusion
• • unstable dose or type of anti-hypertension drug
• • taking the drug or health food which will change the body weight